Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis
Frontiers in Oncology · 02.10.2023 · 13
DOI: 10.3389/fonc.2023.1238332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 02.10.2023. Verfasst von Songhua Cai und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Ac…. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Although many CTC isolation and detection methods can provide information on cancer cell counts, downstream gene and protein analysis remain incomplete. Therefore, it is crucial to develop a technology that can provide comprehensive information on both the number and profile of CTC.
Methods
In this study, we developed a novel microfluidics-based CTC separation and enrichment platform that provided detailed information about CTC.
Results
This platform exhibits exceptional functionality, achieving high rates of CTC recovery (87.1%) and purification (∼4 log depletion of WBCs), as well as accurate detection (95.10%), providing intact and viable CTCs for downstream analysis. This platform enables successful separation and enrichment of CTCs from a 4 mL whole-blood sample within 15 minutes. Additionally, CTC subtypes, selected protein expression levels on the CTC surface, and target mutations in selected genes can be directly analyzed for clinical utility using immunofluorescence and real-time polymerase chain reaction, and the detected PD-L1 expression in CTCs is consistent with immunohistochemical assay results.
Conclusion
The microfluidic-based CTC enrichment platform and downstream molecular analysis together provide a possible alternative to tissue biopsy for precision cancer management, especially for patients whose tissue biopsies are unavailable.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen,…
- Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
- Institute of Cancer Control, Cancer Hospital of Xinjiang Medical University, Urumqi, China.
- Shenzhen Futian Research Institute, City University of Hong Kong, Shenzhen, China.
- Department of Medical Affairs, Cellomics (ShenZhen) Limited, Shenzhen, China.
Zitieren
APA
Cai, S., Deng, Y., Wang, Z., Zhu, J., Huang, C., Du, L., Wang, C., Yu, X., Liu, W., Yang, C., Wang, Z., Wang, L., Ma, K., Huang, R., Zhou, X., Zou, H., Zhang, W., Huang, Y., Li, Z., …, & Yu, Z. (2023). Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1238332
Vancouver
Cai S, Deng Y, Wang Z, Zhu J, Huang C, Du L, et al. Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1238332
BibTeX
@article{Cai2023,
author = {Cai, Songhua and Deng, Youjun and Wang, Zhe and Zhu, Junyu and Huang, Chujian and Du, Longde and Wang, Chunguang and Yu, Xiangyang and Liu, Wenyi and Yang, Chenglin and Wang, Zhe and Wang, Lixu and Ma, Kai and Huang, Rui and Zhou, Xiaoyu and Zou, Heng and Zhang, Wenchong and Huang, Yan and Li, Zhi and Qin, Tiaoping and Xu, Tao and Guo, Xiaotong and Yu, Zhentao},
title = {Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1238332}
}
EUVIMED